Physician profile
Guillermo Ortiz
NPI 1407828445
$5,833.93
in general payments reported to CMS, 2019-2025
34 companies · $536 in 2025
The $536 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,190 · 2020: $452 · 2021: $746 · 2022: $577 · 2023: $507 · 2024: $826 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,682 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,681.67 |
| Education | $187.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $1,594.35 | 2019-2021 | |
| Celularity INC. | $600.00 | 2019-2020 | |
| Abbvie INC. | $430.45 | 2019-2023 | |
| Exeltis, USA INC. | $368.05 | 2019-2025 | Slynd |
| Evofem Biosciences, INC. | $315.77 | 2021-2025 | Phexxi, Solosec, Phexx |
| Astellas Pharma US INC | $282.69 | 2024-2025 | Veozah |
| Baxter Healthcare | $261.50 | 2024-2025 | Tisseel |
| Mayne Pharma Commercial LLC | $252.85 | 2022-2025 | |
| Amgen INC. | $211.26 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $203.04 | 2019-2024 | Gardasil 9, Gardasil |
| Exact Sciences Corporation | $199.60 | 2023-2025 | Cologuard Collection Kit |
| Organon LLC | $179.39 | 2022-2025 | Nexplanon, Jada System |
| Lupin INC. | $167.17 | 2019-2021 | |
| Applied Medical Resources Corporation | $143.89 | 2021 | |
| Dysis Medical, INC. | $64.06 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $60.66 | 2019-2022 | |
| Ethicon US, LLC | $59.34 | 2022-2025 | Stratafix, Dermabond Prineo |
| Millicent US INC | $52.84 | 2025 | Femlyv |
| Therapeuticsmd, INC. | $48.02 | 2021-2022 | |
| Myovant Sciences INC. | $47.50 | 2021-2022 | |
| Pfizer INC. | $41.30 | 2020-2021 | |
| Agile Therapeutics, INC. | $40.14 | 2022 | |
| Davol INC. | $29.95 | 2021 | |
| Avion Pharmaceuticals | $27.45 | 2021-2023 | Balcoltra |
| Baudax Bio INC. | $22.04 | 2021 | |
| Aspira Women'S Health INC | $21.65 | 2019 | |
| Hologic Sales and Service, LLC | $20.43 | 2024 | Myosure Tissue Removal Device, Novasure |
| Olympus America INC. | $16.16 | 2019 | |
| Sumitomo Pharma America, INC. | $15.22 | 2023 | Myfembree |
| Kowa Pharmaceuticals America, INC. | $14.95 | 2023 | Seglentis |
| Coopersurgical, INC. | $14.91 | 2023 | Mara Console |
| Channel Medsystems, INC. | $13.97 | 2024 | |
| Allergan, INC. | $13.33 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guillermo Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.